Data Supports Further Investigation of Mesothelioma Virotherapy

Oncolytics Biotech presented data that indicates malignant mesothelioma cells are sensitive to certain viruses. Their presentation titled “Combination Immunotherapy and Oncolytics Virotherapy for the Treatment of Malignant Mesothelioma” discussed in vitro data showing mesothelioma cells could be suitable targets for reoviruses which could then attack and compromise them.

The company currently has 7 ongoing phase I and phase II trials though none are currently for mesothelioma patients. Reoviruses, which the company is investigating, are generally gastrointestinal infections with the most common form being the rotavirus.

The goal of virotherapy is to isolate and reprogram viruses to only attack cancerous cells. It is still a relatively undeveloped field within cancer research but progress is being made.